Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 30, 2019
Event: Entry into a Material Definitive Agreement regarding warrant exercises and issuance.
Key Financial Metrics
This filing reports a specific capital transaction rather than periodic financial performance. The filing text does not provide values for revenue, profit, cash flow, margins, or total debt.
- Aggregate Exercise Proceeds: Approximately $4.2 million.
- Warrants Exercised:
- 270,313 shares at $3.1445 per share.
- 837,500 shares at $4.00 per share.
- New Warrant Issued: Right to purchase up to 1,200,000 shares at $4.50 per share.
- New Warrant Term: Six years.
Material Changes
The primary material change is the increase in cash proceeds of approximately $4.2 million resulting from the exercise of outstanding warrants by Armistice Capital Master Fund, Ltd. Additionally, the company's potential dilution increased due to the issuance of a new warrant for 1,200,000 shares as an inducement for the exercise.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The transaction was structured as an inducement for the warrant exercise. The new warrant and shares were offered in reliance upon exemptions under Rule 506 of Regulation D and Section 4(a)(2) of the Securities Act of 1933. The company agreed to file a registration statement covering the resale of the new warrant shares.
Investor Verification Checklist
- Verify the actual cash receipt of the $4.2 million proceeds in the company's next quarterly or annual report.
- Confirm the filing of the registration statement for the resale of the 1,200,000 new warrant shares.
- Review the full text of the Warrant Exercise Agreement (Exhibit 10.1) for any additional covenants or conditions not summarized in the 8-K.
- Assess the impact of the new warrant (1.2 million shares at $4.50) on future dilution scenarios.